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a b s t r a c t
Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease
(COPD) and in the induction of corticosteroid (CS) insensitivity. Chronic ozone exposure leads to a model
of COPD with lung inﬂammation and emphysema. Mitogen-activated protein kinase phosphatase-1
(MKP-1) may underlie CS insensitivity in COPD. We determined the role played by MKP-1 by studying
the effect of corticosteroids in wild-type C57/BL6J and MKP-1/ mice after chronic ozone exposure.
Mice were exposed to ozone (3 ppm, 3 h) 12 times over 6 weeks. Dexamethasone (0.1 or 2 mg/kg;
intraperitoneally) was administered before each exposure. Mice were studied 24 h after ﬁnal exposure.
In ozone-exposed C57/BL6J mice, bronchial hyperresponsiveness (BHR) was not inhibited by both doses
of dexamethasone, but in MKP-1/ mice, there was a small inhibition by high dose dexamethasone
(2 mg/kg). There was an increase in mean linear intercept after chronic ozone exposure in both strains
which was CS-insensitive. There was lesser inﬂammation after low dose of dexamethasone in MKP-1/
mice compared to C57/Bl6J mice. Epithelial and collagen areas were modulated in ozone-exposed MKP-
1/ mice treated with dexamethasone compared to C57/Bl6J mice. MKP-1 regulated the expression of
MMP-12, IL-13 and KC induced by ozone but did not alter dexamethasone's effects. Bronchial
hyperresponsiveness, lung inﬂammation and emphySEMa after chronic exposure are CS-insensitive,
and the contribution of MKP-1 to CS sensitivity in this model was negligible.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
1. Introduction
Oxidative stress is a feature of the airways and lungs of patients
with chronic obstructive pulmonary disease (COPD), resulting from
the release of reactive oxygen and nitrogen species from inﬂamma-
tory and immune cells in the airways and from the direct exposure to
oxidants present in cigarette smoke or environmental pollutants
(Chung and Marwick, 2010). Oxidative stress plays an important role
in the pathogenesis of COPD since cigarette smoke and particulate
exposure are potent inducers of oxidative stress (Repine et al., 1997;
Risom et al., 2005; Chung and Adcock, 2008). The mechanisms and
pathways by which oxidative stress can lead to chronic inﬂammation
and emphysema have been investigated in mouse models of cigar-
ette exposure (Shapiro, 2007; Taraseviciene-Stewart and Voelkel,
2008). Thus, the importance of oxidative stress in inducing emphy-
sema has been demonstrated in nuclear factor-E2-related factor-2
(Nrf2) knockout mice, which, through their diminished capacity to
mount antioxidant defences, develop increased susceptibility to
emphysema and lung inﬂammation following cigarette smoke expo-
sure (Rangasamy et al., 2004). Furthermore, direct exposure of mice
to an oxidant gas, ozone, results in emphysema and chronic lung
inﬂammation reminiscent of COPD (Triantaphyllopoulos et al., 2011).
Oxidant stress also causes bronchial hyperresponsiveness resulting
from an increase in contractility of the airways (Li et al., 2011).
Corticosteroids (CSs) are widely used in the treatment of
chronic airway inﬂammatory diseases. Although they are the most
potent anti-inﬂammatory agent used in the treatment of asthma,
they are not always effective as in patients with severe asthma and
COPD. Several mechanisms may underlie CS insensitivity (Adcock
et al., 2008), which includes the role of the mitogen-activated
protein kinases (MAPK) (Chung, 2011). MAPK phosphatases termi-
nate MAPK activation by dephosphorylating both threonine and
tyrosine residues (Camps et al., 2000). MKP-1 or DUSP-1, the
founding member of this group of at least 10 phosphatases, is an
effective inhibitor of JNK and p38 MAPK. MKP-1 is up-regulated by
oxidative stress and other stimuli such as ultra-violet light, TNFα,
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IL-1 and several toll-receptor ligands (Keyse, 2000). MKP-1 may be
involved in corticosteroid responses since corticosteroids inhibit
p38 MAPK in macrophages from MKP-1þ /þ mice but not in those
from MKP-1 / littermates where there was an inability of corti-
costeroids to inhibit cytokine release from macrophages of these
mice (Abraham et al., 2006). Thus, MKP-1 expression may underlie
CS insensitivity found in various respiratory diseases such as severe
asthma and COPD (Chung, 2011).
In order to investigate whether MKP-1 can modulate the effects
of oxidative stress and their responses to CS, we used a model of
chronic exposure to ozone that leads to alveolar space enlargement
and destruction together with a chronic inﬂammatory process (6).
Although CS have been shown to inhibit the effects of a single
exposure to ozone (Salmon et al., 1998; Toward and Broadley, 2002),
it is not knownwhether they inhibit the effect of multiple exposures
to ozone. We therefore examined the effect of CS in a chronic ozone
model, and determined the role played by MKP-1 by studying the
MKP-1 / mouse.
2. Materials and methods
2.1. Mice
Pathogen-free, 10–12 week old male C57/BL6J mice (Harlan, UK)
and gender-matched MKP-1/ mice (Kennedy Institute, Imperial
College, UK) were housed within ‘maximiser’ ﬁlter-topped cages
(Maximiser, Theseus caging system Inc., Hazelton, PA, USA). The
original MKP-1 null strain provided by Bristol Myers Squibb
(Dorfman et al., 1996) was on a mixed C57/BL6J-129Sv genetic
background. This strain was back-crossed against C57/BL6J over nine
generations, then intercrossed heterozygotes and MKP-1þ /þ and
MKP-1 / mice were identiﬁed by PCR-based screen of genomic
DNA from tail snips. MKP-1 / colonies are identical in genetic
background (almost pure C57/BL6J), but differ only at the MKP-1
locus. We therefore used wild type C57/BL6J as controls. The protocols
were approved by the Imperial College Biosciences group and
performed under a license from the Home Ofﬁce UK government.
2.2. Study design and methods
The experiments were performed within the legal framework
of the United Kingdom under a Project License granted by the
Home Ofﬁce of Her Majesty's government. The researchers hold
Personal Licenses to perform the experiments described here.
MKP-1 / and C57/BL6J were investigated and received ozone
twice a week for a period of 6 weeks (a total of 12 exposures).
Ozone was generated from an ozoniser (Model 500 Sander
Ozoniser, Germany), mixed with air for 3 h at 2.5 parts per million
(ppm) in a sealed Perspex container. Control animals received
medical air only over the equivalent period. Ozone concentration
was continuously monitored with an ozone probe (ATi Technolo-
gies, Ashton-U-Lyne, UK). Ozone exposure was carried out in
3 groups: (i) ozone and vehicle, (ii) ozone and 0.1 mg/kg dexa-
methasone and (iii) ozone and 2 mg/kg dexamethasone. During
the ﬁnal 4 weeks of ozone exposure, animals received either
dexamethasone or vehicle 2 h prior to each exposure to ozone
(i.e. 8 injections in all). After 2 weeks of ozone exposures, mice
received intraperitoneal (i.p.) injections of either 0.1 mg/kg or
2 mg/kg dexamethasone (D4902-1G Sigma Aldrich, USA) dissolved
in 0.1 ml Dulbecco phosphate buffered saline (PBS) (Sigma, Dorset,
UK). One group exposed to ozone received the same volume
(0.1 ml) of PBS as vehicle. Mice were studied 24 h after the last
exposure to ozone.
2.3. Measurement of bronchial hyperresponsiveness
24 h following exposure, mice were anesthetized with an intra-
peritoneal injection of anesthetic solution containing midazolam
(Roche Products Ltd., Welwyn Garden City, UK) and Hypnorm
(0.315 mg/ml fentanyl citrate and 10 mg/ml ﬂuanisone; Janssen
Animal Health, Wantage, UK). Mice were tracheostomized and
ventilated (Mini Vent type 845, Hugo Sach Electronic, Germany; rate:
250 breaths/min and tidal volume: 250 μl). Mice were monitored in a
whole body plethysmograph with a pneumotachograph connected to
a transducer (EMMS, Hants, UK). Transpulmonary pressure was
assessed via an esophageal catheter. Instantaneous calculation of
pulmonary resistance (RL) was obtained. Increasing concentrations
of acetylcholine chloride (ACh) (Sigma, Dorset, UK) (4–256 mg/ml)
were administered with an Aeronebs Lab Micropump Nebulizer
(EMMS, Hants, UK), and RL was recorded for a 3-min period following
each concentration. RL after each concentration was expressed as
percentage change from baseline RL measured following nebulized
PBS (Sigma, Dorset, UK). The concentration of acetylcholine required
to increase RL by 100% from baseline was calculated (PC100).
2.4. Measurement of inﬂammation and mean linear intercept, Lm
Following an overdose of pentobarbitone anesthetic, the lungs
were dissected out and were inﬂated by injecting fresh 4% paraf-
ormaldehyde into the lungs to provide 25 cm of water pressure for
at least 4 h. Lungs were processed using a histological automatic
tissue processor and embedded in parafﬁn. Parafﬁn blocks were
sectioned to expose the maximum surface area of lung tissue in the
plane of the bronchial tree. 5 μm sections cut and stained with
haematoxylin and eosin and Masson's trichrome stain were point-
counted to assess morphological changes of airway epithelium,
collagen deposition and airway smooth muscle (ASM) mass.
The mean linear intercept (Lm) is a measure of the surface area-
to-volume ratio representing a stereological metric of alveolar size.
Using a reticule with a Thurlbeck grid comprising 5 lines (each
550 μM long) and 10 ﬁelds per section was assessed at random.
Fields with airways or vessels were avoided by moving one ﬁeld in
any one direction. The total score for each section was determined
by counting the number of times the alveolar wall tissue inter-
cepted each line. Lm was calculated by dividing the length of the
line by the number of tissue intercepts counted.
The inﬂammatory response observed in the haematoxylin–eosin-
stained lung sections was scored on a 0–3 scale as follows: 0¼no
inﬂammatory response, 1¼mild inﬂammation with foci of inﬂam-
matory cells in bronchial or vascular wall and in alveolar septa;
2¼moderate inﬂammation with patchy inﬂammation or localized
inﬂammation in walls of bronchi or blood vessel and alveolar septa
and less than 1/3 of lung cross-sectional area is involved; and
3¼severe inﬂammation with diffuse inﬂammatory cells in walls of
bronchi or blood vessels, and alveoli septa; between one third to two
thirds of the lung area is involved.
All counts on histology sections were performed by one inves-
tigator who was unaware of the treatment protocol.
2.5. Reverse transcription, and real-time PCR of mouse lungs
RNA was extracted from frozen stored lung tissue using an
RNeasy Mini kit (Qiagen). RNA yield was then ampliﬁed via PCR
using an Omniscript Reverse Transcriptase kit (Qiagen) and stored
at 80 1C until required. 0.5 μg per sample of RNA was used to
synthesize single-stranded complementary DNA (cDNA) using random
hexamers and an avian myeloblastosis virus reverse transcriptase
(Promega). The cDNA generated was used as a template in subsequent
real-time PCR analyses to determine transcript levels by using Rotor
Gene (Rotor Gene 3000, Corbett Research) and QuantiTech SYBR
M. Pinart et al. / European Journal of Pharmacology 744 (2014) 108–114 109
Green PCR Master Mix Reagent (Qiagen). Sequences of forward and
reverse primers for MMP-12, IFNγ, IL-13 and KC were designed using
Primer Express software (version 2; Applied Biosystems, Foster City,
CA). Cycling conditions were as follows: step 1, 15 min at 95 1C; step 2,
20 s at 94 1C; step 3, 20 s at 55 1C; step 4, 20 s at 72 1C, repeating step
2 to step 4, 55 times. Gene expression was expressed as a ratio of the
gene of interest mRNA to GAPDH mRNA.
2.6. Data analysis
Data are presented as mean7S.E.M. Those variables following a
normal distribution were submitted to one-way ANOVA analysis of
variance followed by Bonferroni post-hoc testing for comparisons
between two individual groups. Otherwise, Kruskal–Wallis test was
used followed by Mann–Whitney–Wilcoxon test for comparisons
between two individual groups. Statistical signiﬁcance was accepted
at P-value less than 0.05.
3. Results
3.1. Effect of dexamethasone on chronic-exposed ozone-induced BHR
Following ozone exposure, there was an increase in BHR in all
groups of mice compared to control in both strains (Fig. 1A and B). In
MKP-1 / mice, ozone caused an increase in RL compared to air-
exposed mice, at all doses except for the highest concentration
(256mg/ml) of ACh, and at the intermediate concentrations of 32
and 64mg/ml for the groups treated with either 0.1 mg/kg dexametha-
sone or 2mg/kg dexamethasone (Fig. 1B). Furthermore, ozone-exposed
MKP-1 / mice treated with vehicle showed a signiﬁcant increase in
RL compared to 2mg/kg dexamethasone-treated mice, at concentra-
tions between 8 and 128mg/ml ACh. When comparing between
strains, signiﬁcant differences were seen at the highest dose of ACh in
mice administered the highest dose of dexamethasone (Po0.01).
When bronchial responsiveness was assessed as PC100, the
decrease in PC100 was not inhibited by the two doses of dexa-
methasone in C57/Bl6J mice (Fig. 1C). In MKP-1 / mice, there
was still a signiﬁcant reduction in PC100 after ozone exposure after
0.1 mg/kg dexamethasone but not after the 2 mg/kg dose indicat-
ing a potential reversal of ozone induced BHR. Thus, in both
strains, there was induction of corticosteroid insensitivity, but
MKP-1 / mice compared to C57/BL6J mice responded partially to
high-dose dexamethasone.
3.2. Lung inﬂammation scores
Ozone-exposed groups of C57/BL6J mice showed an increase in
inﬂammation scores with peribronchial and perivascular inﬂamma-
tory cell inﬁltrates in lung sections compared to air-exposed mice,
particularly in the group treated with 0.1 mg/kg dexamethasone
(Po0.01, Fig. 2). Similar ﬁndings were observed in the MKP1 /
mice, expect for the group treated with low dose dexamethasone that
led to lower lung inﬂammation scores. Lower inﬂammatory scores
were observed in the ozone-exposed MKP-1 / mice treated with
0.1 mg/kg dexamethasone compared to the C57/BL6J mice (Po0.05).
3.3. Mean linear intercept, Lm
Lm increased in C57/BL6J and MKP-1 / ozone-exposed mice
compared to air-exposed mice (both Po0.01, compared to unex-
posed mice) (Fig. 3). Lm was still increased in both strains after
ozone exposure following dexamethasone pretreatment at both
doses. However, MKP-1 / mice exposed to ozone and receiving
the low dose dexamethasone had a lower Lm when compared to
ozone-exposed C57/Bl6J mice (Po0.05).
3.4. Effect on epithelial, airway smooth muscle and collagen areas
At baseline, MKP-1 / mice showed a signiﬁcantly lower epithe-
lial area compared to C57/Bl6J mice (Fig. 4A). High dose dexametha-
sone increased epithelial area in C57/BL6J ozone-exposed mice, an
Fig. 1. Airway hyperresponsiveness. Concentration–response curves to acetylcho-
line (ACh) (Panels A and B) and log provocative concentration of ACh required to
increase lung resistance (RL) by 100% from baseline (log PC100) (Panels C) of C57/
BL6J and MKP-1/ mice exposed to air or to multiple ozone exposures over
6 weeks. Data expressed as mean7S.E.M. Horizontal bars indicate mean. For
Panels A and B, *Po0.05; **Po0.01: ozone compared to air-exposed mice;
aPo0.05; aaPo0.01, ozone-exposed and treated with 0.1 mg/kg dexamethasone
compared to air-exposed mice; Po0.05; Po0.01: ozone-exposed and treated with
2 mg/kg dexamethasone compared to air-exposed mice; $Po0.05: ozone-exposed
mice treated with saline (vehicle) compared to ozone-exposed and treated with
2 mg/kg dexamethasone. For Panel C, *Po0.05; **Po0.01; ***Po0.001.
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effect not seen in MKP-1/ mice, indicating control of epithelial cell
area by dexamethasone dependent on MKP-1. In C57/BL6J mice, the
high dose of dexamethasone decreased airway smooth muscle area,
an effect that persisted in MKP-1/ mice (Fig. 4B). High dose
dexamethasone while having no effect on collagen area in C57/BL6J
ozone-exposed mice increased it in MKP-1/ ozone-exposed mice
(Fig. 4C). Thus, there was a role for MKP-1 in modulating the effect of
dexamethasone on the epithelial and collagen surface area following
ozone exposure.
3.5. Effect on gene expression of MMP-12, IFNγ and IL-13
Baseline mRNA expression of MMP-12, KC and IL-13, but not of
IFNγ, was increased in MKP-1/ mice (Table 1).
3.5.1. MMP-12
In ozone-exposed C57/BL6J mice, there was an enhanced
expression of MMP-12 after ozone exposure (Po0.05, Fig. 5A)
and dexamethasone (2.0 mg/kg) had no effect on this increased
MMP-12 expression. By contrast, in MKP-1/ mice, there was no
effect of ozone exposure and neither did dexamethasone have
an effect.
3.5.2. IL-13
There was no effect of dexamethasone on the expression of
IL-13 in ozone-exposed C57/BL6J but there was a reduction in the
expression of IL-13 in MKP-1/ mice (Po0.05, Fig. 5B).
3.5.3. IFNγ
There was no effect of ozone or of dexamethasone on IFNγ
expression in both strains (Fig. 5C).
Fig. 2. Lung inﬂammation. Representative light microscopic lung sections from
C57/Bl6 and MKP-1/ mice showing the inﬂammatory response in the lungs
following exposure to ozone alone (Panels B and E) and the effect of high dose
dexamethasone (Panels C and F), compared to air-exposed mice (panels A and D).
Bar in Panel F is 10 μM. Panel G shows the individual inﬂammation scores in the
lungs of C57/BL6J and MKP-1 / mice exposed to ozone over 6 weeks. *Po 0.05;
**Po0.01.
Fig. 3. Mean linear intercept (Lm). Representative light microscopic lung sections
from C57/Bl6 and MKP-1/ mice showing alveolar damage and enlargement in
the lungs following exposure to ozone alone (Panels B and E) and the effect of high
dose dexamethasone (Panels C and F), compared to air-exposed mice (Panels A and
D). Bar in Panel F is 20 μM. Panel G shows the individual Lm values measured in
lung sections of C57/BL6J and MKP-1 / mice exposed to ozone over 6 weeks.
Horizontal bar indicates mean values. *Po 0.05; **Po0.01.
Fig. 4. Changes in airway wall. Individual and mean% of area of bronchial wall
occupied by epithelium (Panel A), airway smooth muscle (ASM) (Panel B) and
collagen (Panel C) in C57/BL6J MKP-1/ mice after chronic exposure to ozone or
air, as determined by point-counting. The ozone-exposed mice were treated with
saline (vehicle) or with 0.1 mg/kg or 2.0 mg/kg dexamethasone (Dex) prior to each
exposure. *Po 0.05; **Po0.01; ***Po0.001.
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3.5.4. KC
In C57/BL6J mice, there was no effect of ozone exposure or of ozone
and dexamethasone treatment on the expression of KC. However, in
MKP1 / mice, KC gene expression was reduced after ozone expo-
sure, but this was not affected by dexamethasone (Fig. 5D).
4. Discussion
We determined the role of MKP-1 on the effects of corticosteroids
in a chronic model of ozone exposure of chronic lung inﬂammation
and emphysema (Triantaphyllopoulos et al., 2011). We used a well-
documented MKP-1 knock-out mouse (Dorfman et al., 1996) whose
macrophages demonstrate CS insensitivity (Abraham et al., 2006) to
determine whether the knock-down of MKP-1 would affect, ﬁrst, the
response of the lungs to chronic ozone exposure and secondly,
the effect of dexamethasone on the response of the lungs to ozone.
The overall ﬁndings of the study are now summarized in Table 2.
Overall, dexamethasone had no effect in reversing the bronchial
hyperresponsiveness, mean linear intercept and inﬂammation, and
the expression of the emphysema-related genes, MMP-12, IL-13 and
IFNγ, and the neutrophil-associated gene, KC induced by ozone.
Some effects of dexamethasone were observed on epithelial and
airway smooth muscle areas but these were not affected by ozone
exposure. In the light of previous studies where CS suppressed BHR
and lung inﬂammation caused by single exposure to ozone (Salmon
et al., 1998; Toward and Broadley, 2002), we conclude that the
chronic ozone exposure led to a state of CS insensitivity. In addition,
we have also shown that in C65/BL6 mice the effect of a single
exposure to ozone is blocked by dexamethasone, in contrast to the
multiple exposure model (unpublished data). In addition to BHR and
lung inﬂammation, the emphysematous process and the expression
of emphysema-related genes are also insensitive to CS.
We found that MKP-1 had a little effect on BHR, inﬂammation
and emphysema induced by chronic ozone exposure (Table 2).
High dose dexamethasone caused some reversal of BHR induced
by chronic exposure to ozone in MKP-1 / mice indicating that
MKP-1 may partly contribute to the CS insensitivity. There was
Fig. 5. Lung expression of inﬂammatory genes. Individual and mean fold-change from air control for gene expression of MMP-12 (Panel A), IL-13 (Panel B), IFNγ (Panel C),
and KC (Panel D) in lungs of mice exposed to either air or ozone (O3) or to ozone but pre-treated with 2.0 mg/kg dexamethasone (DEX) in C57/BL6J and in MKP-1 / mice
following chronic exposure to ozone. For each strain, the data has been normalized to expression in air-exposed mice alone. Bars show mean. *Po 0.05; **Po0.01.
Table 1
Inﬂammatory gene expression in the lungs of C57/Bl6J and MKP-1 / mice.
Inﬂammatory gene C57/BL6J MKP-1 / P value
MMP-12 1.78370.556 10.01271.566 o0.001
IL-13 3.51871.832 85.142726.492 0.010
IFN-γ 1.77070.996 18.776710.094 NS
KC 1.34570.356 5.39771.692 0.021
n¼6 in each group. Results shown as mean 7S.E.M.
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also some reversal of the lung inﬂammatory scores observed with
low dose but not high dose dexamethasone in MKP-1/ mice.
The lack of effect of dexamethasone on the emphysema as
measured by the increase in mean linear intercept, Lm, induced
by chronic ozone exposure was also observed in MKP-1 / mice,
indicating that MKP-1 is neither involved in the induction of
emphysema nor in the effect of corticosteroids on emphysema.
While ozone exposure did not change epithelial, airway smooth
muscle or collagen areas, dexamethasone while decreasing ASM
area, increased epithelial and collagen areas. MKP-1 modulated
these changes in epithelial and collagen areas induced by corti-
costeroids.
There are various indications that MKP-1 could be involved in
controlling the inﬂammatory response to oxidants. MKP-1 deﬁ-
ciency is associated with an increase in the production of many
cytokines including TNF-α, IL-6, IL-1β (Chen et al., 2002; Shepherd
et al., 2004; Zhao et al., 2005), which is in agreement with the large
increase in gene expression of KC, IL-13 and MMP-12 in the lungs of
unexposed MKP-1 / mice compared to wild-type mice. Under
baseline conditions, MKP-1 may act as a brake on the expression of
various inﬂammatory cytokines possibly through down-regulating
the activation of MAPKs such as p38 and JNK in the lungs. However,
the regulation of various genes under conditions of oxidative stress
is more complex. On chronic exposure to ozone, the expression of
MMP-12, IL-13 and KC was down-regulated in MKP-1/ mice,
indicating that MKP-1 may prevent the inhibition of oxidative
stress-induced genes in the lung. MKP-1 did not contribute to the
modulation of dexamethasone on the expression of MMP-12, IL-13
and KC under conditions of oxidative stress.
A lack of MKP-1 has been proposed in the genesis of corticoster-
oid insensitivity. Corticosteroids are known to induce MKP-1 in
pulmonary tissues (Kelly et al., 2012), in bronchoalveolar macro-
phages (Bhavsar et al., 2008) and in human airway epithelial cells
(Kaur et al., 2008). The muted induction of MKP-1 expression in
alveolar macrophages of severe asthmatics is correlated with
corticosteroid insensitivity of these cells (Bhavsar et al., 2008).
There is some evidence that MKP-1 may be essential for the effect
of CS, and a deﬁciency of MKP-1 may cause corticosteroid insensi-
tivity. Thus, glucocorticoid receptor activation appears to be essen-
tial for corticosteroid-mediated MKP-1 induction in macrophages
(Bhattacharyya et al., 2007), since there are putative glucocorticoid
response elements (GRE) binding sites on their promoter regions
(Tchen et al., 2010). MKP-1 may be involved in corticosteroid
responses since corticosteroids inhibit p38 MAPK in macrophages
from MKP-1þ /þ mice but not in those from MKP-1/ littermates;
this was accompanied by an inability of corticosteroids to inhibit
cytokine release from macrophages of MKP-1/ mice (Abraham
et al., 2006). Previous studies performed in bone-marrow derived
macrophages from MKP-1/ mice have reported glucocorticoid-
mediated inhibition of phosphorylation of p38 MAPK but not of
ERK-1 and ERK-2 (Maier et al., 2007). Studies in our MKP-1 model
indicate that MKP-1 would prevent the expression of ozone-
induced cytokines and partly improve the response of BHR and
lung inﬂammation to CS, contrary to our expectations.
One potential explanation for these ﬁndings relate to the possibility
that MKP-1 is inactivated by oxidation leading to greater susceptibility
to proteasome degradation after chronic exposure (Kamata et al.,
2005). The redox state of MKP-1 may determine the response of the
lungs to ozone, particularly after chronic oxidative stress of ozone
exposure, such that the chronic-exposed mice would behave like a
partially-depleted MKP-1 mouse. On the other hand, MKP-1 can be
phosphorylated by MAPKs such as ERK, which protects MKP-1 from
proteasome-mediated degradation (Sohaskey and Ferrell, 2002). In
addition, ERK can mediate the induction of MKP-1 in macrophages.
Thus, the level of activity of ERK and possibly of other kinases may
determine in turn the activity of MKP-1.
4.1. Conclusion
We have shown that chronic exposure to ozone leads to a
corticosteroid-insensitive model of BHR, emphysema and lung
inﬂammation. MKP-1 may increase the expression of MMP-12,
IL-13 and KC in the presence of ozone exposure, but is not involved
in the effect of corticosteroids. However, MKP-1 may modulate to a
small extent the effects of corticosteroids on ozone induction of
BHR, and inﬂammation, with a greater contribution to the epithe-
lial and collagen changes in the airways, representative of the
remodelling process.
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Table 2
Summary of involvement of MKP-1 on the effects of ozone and on the effects of dexamethasone on ozone's effect.




Effect of dexamethasone on ozone's
effects




↑ 0 0 ↓ (hd)a
Mean linear intercept, Lm ↑ 0 0 0
Lung inﬂammatory score ↑ 0 0 ↓ (ld)b
Epithelial area (%) 0 0 ↑ (hd)a ↓ (ld)b
Airway smooth muscle area
(%)
0 0 ↓ (hd)a 0
Collagen area (%) 0 0 ↑ (ld)b ↓ (hd)a
MMP-12 gene expression ↑ ↑ 0 0
IL-13 gene expression 0 ↑ 0 0
IFN γ gene expression 0 0 0 0
KC gene expression 0 ↑ 0 0
a hd: high dose dexamethasone (2 mg/kg).
b ld: low dose dexamethasone (0.1 mg/kg).
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